Exhibit 99.2

CDEX, Inc. Appoints Malcolm H. Philips, Jr. as President and Chief Executive
Officer Monday June 11, 9:00 am ET

Founding CEO Returns to Lead Company's Expansion in Health and Security Markets

TUCSON, AZ--(MARKET WIRE)--Jun 11, 2007 -- CDEX, Inc. (OTC BB:CEXI.OB - News),
the developer of innovative systems for substance detection and verification,
announced today that Malcolm Philips has been named President and Chief
Executive Officer. Mr. Philips was the President, CEO and Chairman of the Board
of CDEX from its inception until he left the Company in early 2006. Since
December 2006, Mr. Philips has been a special advisor to the Board and Mr. Tim
Shriver, who has been serving as acting President and CEO, to consolidate
operations in Tucson, Arizona. With completion of the transition and
consolidation, the senior management team of Mr. Philips as CEO and Mr. Shriver
as Senior Vice President of Technical Operations will continue to lead the
company.

"In the last four months, the CDEX Team has not only consolidated offices in
Tucson, but also expanded the ValiMed(TM) Medical Validation System product line
and Medication Signature Library, upgraded the Methamphetamine Detection Unit
for a second round of beta testing and prepared the ValiMed(TM) LVM (a mobile,
battery operated fentanyl detector) for beta testing," said Mr. Philips. "With
the announcement of the launch of our expanded ValiMed(TM) product line
yesterday, and having additional products close to launch, we feel very well
positioned for the future."

CDEX, Inc. (www.cdex-inc.com) is the developer of the ValiMed(TM) Medication
Validation System. Using Enhanced Photoemission Spectroscopy, ValiMed(TM)
quickly validates high-risk medication admixtures, as well as returned narcotics
to provide an increased level of patient safety. ValiMed(TM) compares a
medication's spectroscopic signature to the Medication Signature Library and
returns an easy to understand "validated" or "not validated" result, requiring
no user interpretation. In conjunction with priority requests from existing and
future clients, CDEX is continuing to build its signature library, which
currently contains over 70 unique pharmaceutical signatures and is expected to
grow to over 150 by the end of 2007.

"The vision and growth strategy of Mr. Philips and Mr. Shriver is fully
supported by the CDEX Board of Directors," said Dr. B.D. Liaw, Chairman of the
Board. "We have been pleased with the speed and results of the Tucson
consolidation and look forward to their leadership for the future."

About CDEX, Inc.

CDEX, Inc. is a technology development company with a current focus on
developing and marketing products using chemical detection and validation
technologies. At present, CDEX is devoting its resources to two distinct areas:
(1) identification of substances of concern (e.g., explosives and illegal drugs
for homeland security); and (2) validation of substances for
anti-counterfeiting, brand protection and quality assurance (e.g., validation of
prescription medication and detection of counterfeit or sub-par products for
brand protection). ValiMed(TM) is a CDEX solution for the healthcare market.
Corporate headquarters and research and development facilities for CDEX are
located in Tucson, Arizona. For more information, visit www.cdex-inc.com and
www.valimed.com.



Any statements made in this press release which contain
information that is not historical are essentially forward-looking. Many
forward-looking statements can be identified by the use of words such as
"expects," "plans," "may," "anticipates," "believes," "should," "intends,"
"estimates," and other words of similar meaning. These statements are subject to
risks and uncertainties that cannot be predicted or quantified and,
consequently, actual results may differ materially from those expressed or
implied by such forward-looking statements. Such risks are detailed from
time-to-time in filings with the Securities and Exchange Commission. There is no
obligation to publicly update any forward-looking statements.

Contact:

     Contact Information:
     Malcolm Philips or Stuart Poteet
     520.745.5172
     Email:  mphilips@cdex-inc.com or spoteet@cdex-inc.com

     Market News First
     Angela Junell
     214-461-3411
     ajunell@MN1.com
     Any statements made




Source: CDEX, Inc.